Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 3(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01244789Phase 2Active Not Recruiting

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

Role: collaborator

NCT02273375Phase 3Active Not Recruiting

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

Role: collaborator

NCT03795272Phase 2Withdrawn

Rucaparib Maintenance Therapy in Advanced Cervical Cancer

Role: collaborator

NCT00028704Phase 3Terminated

Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy

Role: collaborator

NCT00211952Phase 3Suspended

Adjuvant Celecoxib in Completely Resected pN1-2 NSCLC Patients

Role: collaborator

All 5 trials loaded